EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkins B cell lymphoma



Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkins B cell lymphoma



Immunology 89(SUPPL 1): 19




(PDF emailed within 1 workday: $29.90)

Accession: 033654819

Download citation: RISBibTeXText



Related references

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody in the treatment of non-Hodgkins B-cell lymphoma. Biochemical Society Transactions 25(2): 705-708, 1997

Chimeric monoclonal anti-CD20 antibody rituximab for the therapy of B-cell non-Hodgkins lymphoma Treatment results and new clinical studies. Annals of Hematology 77(SUPPL 2): S148, 1998

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochemical Society Transactions 25(2): 705-708, 1997

The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkins lymphoma cell lines. Blood 88(10 SUPPL 1 PART 1-2): 637A, 1996

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. International Journal of Hematology 74(1): 70-75, 2001

Y-90 anti-CD20 monoclonal antibody dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma. Journal of Nuclear Medicine 38(5 SUPPL ): 251P, 1997

Prior therapy with anti-CD20 chimeric antibody may decrease the risk of acute graft-versus-host disease in patients with non-Hodgkins lymphoma receiving allogeneic stem cell transplantation. Blood 96(11 Part 1): 391a, November 16, 2000

IDEC-C2B8 chimeric anti-CD20 antibody Safety and clinical activity in the treatment of patients with relapsed low-grade or follicular non-Hodgkins lymphoma. British Journal of Haematology 93(SUPPL 2): 283, 1996

A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkins lymphoma SWOG 9800. Blood 98(11 Part 1): 843a, November 16, 2001

Radioimmunotherapy with 131I anti-CD20 chimeric monoclonal antibody for relapsed or refractory non-Hodgkins lymphoma. Journal of Nuclear Medicine 43(5 Supplement): 115P-116P, 2002

Treatment of relapsed B-cell non Hodgkins lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies and G-CSF Final report on safety and efficacy. Blood 96(11 Part 1): 732a-733a, November 16, 2000

Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab). Nihon Rinsho. Japanese Journal of Clinical Medicine 60(1): 95-99, 2002

Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 29(3): 473-480, 2002

High-dose, myeloablative radioimmunotherapy of mantle cell non-Hodgkins lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support Results of a pilot study. Cancer Biotherapy & Radiopharmaceuticals 15(4): 408, 2000

Correlation of natural killer cell function/level in young and elderly patients with BCL-6 positive aggressive non-Hodgkins lymphoma treated with chimeric anti-CD20 monoclonal antibody /CHOP or CVP. Blood 98(11 Part 2): 245b, November 16, 2001